RecruitingNot ApplicableNCT06772935

Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer


Sponsor

Affiliated Hospital of Qinghai University

Enrollment

162 participants

Start Date

Jun 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Electroacupuncture treatment of peripheral neuropathy after taxane chemotherapy for breast cancer


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Inclusion Criteria7

  • Breast cancer patients diagnosed by pathology;
  • EOOG score is 0 or 1;
  • The age range for enrollment is between 18 and 75 years old; ④ Accept chemotherapy regimens based on taxane drugs (alone or in combination);
  • ⑤ Previously received taxane chemotherapy for more than 6 months;
  • ⑥ According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higher for more than 2 weeks;
  • ⑦ Voluntarily participate in this clinical trial and sign the informed consent form;
  • Accept regular follow-up visits; ⑨ There is complete pathological data available.

Exclusion Criteria10

  • Non breast cancer patients;
  • Received electroacupuncture treatment within 6 months prior to the start of the study;
  • Patients who experience intolerable toxic side effects during standard dose chemotherapy and terminate the chemotherapy cycle;
  • Prior to enrollment, there was a history of peripheral neuropathy;
  • Unstable heart disease or myocardial infarction within the first 6 months of the study;
  • ⑥ Active skin diseases or surface skin ulcers or infections that cannot tolerate electroacupuncture treatment;
  • ⑦ Uncontrolled epilepsy patients with uncontrolled seizures;
  • ⑧ Merge with other malignant tumor patients;
  • ⑨ Pregnancy and lactation period;
  • ⑩ Refusal to join clinical trial patients

Interventions

BEHAVIORALElectro-acupuncture

A method of acupuncture that combines acupuncture with a certain frequency of electrical stimulation. Electrical stimulation is a mild level of stimulation intensity that is acceptable to the human body.


Locations(1)

Qinghai University Affiliated Hospital

Xining, Qinghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06772935


Related Trials